Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neurocognitive Decline in Patients With Brain Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03508752
Recruitment Status : Recruiting
First Posted : April 26, 2018
Last Update Posted : October 15, 2021
Sponsor:
Information provided by (Responsible Party):
Zabi Wardak, University of Texas Southwestern Medical Center

Brief Summary:
The phase I component of the study is to identify maximal tolerated dose (MTD). The phase II is to evaluate neurocognitive decline.

Condition or disease Intervention/treatment Phase
Brain Metastases Radiation: Stereotactic Radiosurgery Phase 1 Phase 2

Detailed Description:
On review of our experience with treatment for brain metastases since 2009, we have treated over 100 patients with 6 or more metastases in a single radiosurgery session. In the past year and a half (2015-16) there have been approximately 50 patients treated with six or more metastases, indicating that there has been a shift in management of intracranial metastatic disease with increasing preference for radiosurgery despite the presences of greater metastatic burden. The phase I component will accrue 7-15 patients at each dose cohort until the MTD is determined. Once the MTD is reached, the phase II component will commence with a total of 50 patients total enrolled at the MTD, with a study time of 3 years. The primary endpoint of the phase I component is toxicity. The primary endpoint of the phase II component is the change in neurocognitive function, defined by a decline in the Hopkins Verbal Learning Test- Revised delayed recall. Data from the WBRT-alone arm of the PCI-P-120-9801 phase III trial evaluating WBRT plus motexafin gadolinium demonstrated a 30% mean relative decline in the HVLT-R delayed recall score from baseline to 4 months, with a standard deviation of 41% 9,10. More recently, in patients treated with SRS alone for 1-3 metastases versus SRS plus whole brain radiotherapy, the 4-month rates of HVLT-R delayed recall deterioration were 6% and 22% for the SRS alone arm and SRS + whole brain radiotherapy arm, respectively. Given the greater intracranial burden of disease, we estimate the mean relative decline in HVLT-R delayed recall to be intermediate between SRS alone for 1-3 metastases and whole brain radiotherapy. We predict that after SRS for multiple metastases the mean relative decline in delayed recall as 15%, an improvement over the historical control of whole brain radiotherapy alone which had a mean relative decline in HVLT-R delayed recall of 30%.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Trial to Determine the Neurocognitive Decline in Patients With Multiple (>6) Brain Metastases Treated With Distributed Stereotactic Radiosurgery
Actual Study Start Date : December 5, 2017
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2023

Arm Intervention/treatment
Experimental: Radiation
Stereotactic Radiosurgery
Radiation: Stereotactic Radiosurgery
Stereotactic Radiosurgery dose is based on the largest tumor size




Primary Outcome Measures :
  1. Phase I: To determine the toxicity within 60 days from the date of SRS, in patients with a greater intracranial disease burden, defined as 6 or more metastases. [ Time Frame: 60 days ]

    Any subject who receives treatment on this protocol will be evaluated for toxicity. Each patient will be assessed for the development of toxicity according to the study calendar. Toxicity will be assessed according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE), version 5.0.

    The following acute (<30 days) and subacute (>30 days - <60 days) toxicities probably or definitely attributable to the protocol treatment, as defined in CTCAE v5.0, will be dose limiting toxicities (DLT) of the study.

    Grade 3 or higher neurologic toxicity in the below categories:

    • Ataxia
    • Symptomatic Central Nervous System Necrosis which is interfering with ADLs (Activities of Daily Living), or requiring treatment with hyperbaric oxygen, Avastin, or resection. Asymptomatic necrosis present on imaging alone does not constitute DLT.
    • Cerebral Edema (Grade 4)
    • Intracranial Hemorrhage
    • Seizure

    Any Grade 4 or 5 toxicities definitely attributable to the protocol treatment.


  2. Phase II: Determine the cognitive deterioration (HVLT delayed recall) in patients treated with SRS for multiple metastases (from baseline to 4 months) [ Time Frame: 4 months ]

    The Hopkins Verbal Learning Test (HVLT) is a memory test that gives information about memory.

    Each patient will serve as her or his own control, and the relative decline in HVLT-DR (Hopkins Verbal Learning Test- Delayed Recall) score from baseline to 4 month follow-up is defined as

    Δ HVLT-DR = (HVLT-R DR at baseline - HVLT-DR at 4 month follow up) / HVLT-DR at baseline.

    A positive change indicates a decline in function.



Secondary Outcome Measures :
  1. To determine the optimal dose which will provide local control in patients with a greater intracranial disease burden, defined as 6 or more metastases [ Time Frame: 90 days ]
    It is assumed that the optimal dose will be the maximum tolerated dose. However, the maximum tolerated dose may or may not be the most ideal dose balancing benefit and toxicity with the widest therapeutic window.

  2. To determine neurocognitive outcomes [ Time Frame: 3 years ]
    via HVLT (Hopkins Verbal Learning Test) and quality of life via FACT-Br (Functional Assessment of Cancer Therapy) amongst patients treated with > 6 metastases via SRS.

  3. To determine overall survival [ Time Frame: 2 years ]
    overall survival (OS) is defined as the time between date of SRS and date of death

  4. To determine the time to distant brain recurrence [ Time Frame: 3 years ]
    distant brain recurrence is defined as time between date of SRS and development of new metastases

  5. To determine the incidence of salvage WBRT or radiosurgery [ Time Frame: 4 months ]
    WBRT is defined as whole brain radiation therapy

  6. To determine the incidence of development of leptomeningeal disease [ Time Frame: 2 years ]
    Leptomeningeal disease is an exclusion criteria for the study

  7. To prospectively collect treatment time of patients treated for multiple metastases [ Time Frame: 2 years ]
    reported in a routine manner at scheduled times during the trial

  8. Prospectively collect and analyze standard patient demographics [ Time Frame: 3 years ]
    Patient demographics include age in years, performance status using ECOG (Eastern Cooperative Oncology Group)/Zubrod performance scale, and gender

  9. Prospectively collect and analyze histology and mutational/hormone status [ Time Frame: 3 years ]
    Patients' disease status over time

  10. Prospectively collect and analyze the effect of the type of prior systemic therapy on local control, neurocognitive outcome, quality of life and toxicity [ Time Frame: 3 years ]
    Prior systemic therapy includes cytotoxic, targeted, or immune therapy

  11. Prospectively collect and analyze the effect of controlled or uncontrolled systemic disease on local control, neurocognitive outcome, quality of life and toxicity [ Time Frame: 3 years ]
    How patients are affected by systemic disease over time

  12. Prospectively collect and analyze neurologic symptoms at the time of SRS [ Time Frame: 3 years ]
    Symptoms at time of stereotactic radiosurgery

  13. Prospectively collect and analyze the number of brain metastases and relation to local control, neurocognitive outcome, quality of life, and toxicity [ Time Frame: 3 years ]
    How the number of brain metastases affects patients' health over time

  14. Prospectively collect and analyze the size of treated brain metastases [ Time Frame: 3 years ]
    Measured in millimeters/centimeters

  15. Prospectively collect and analyze total brain metastases volume and relation to local control, neurocognitive outcome, quality of life, and toxicity [ Time Frame: 3 years ]
    Total brain metastases volume (cc)

  16. Prospectively collect and analyze the total treatment time [ Time Frame: 3 years ]
    Treatment time measured in hours, minutes, and seconds

  17. Prospectively collect and analyze whole brain integral dose, V8, V10, and V12 and relation to toxicity [ Time Frame: 3 years ]
    assessed by CTCAE v5.0

  18. Prospectively collect and analyze hippocampal dose and relation to neurocognitive decline [ Time Frame: 3 years ]
    Hippocampal dose measured in cGy (centigray); neurocognitive decline assessed by HVLT (Hopkins Verbal Learning Test)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. ECOG Performance Score of 2 or better/Karnofsky Performance score of 50-60 or better.
  3. Biopsy-proven non-hematopoietic malignancy, except for germ cell cancer. Small cell lung carcinoma is eligible for this study
  4. Six or more metastases on diagnostic or treatment planning imaging, which include either CT Brain (with contrast) or MR Brain (with or without contrast) imaging.
  5. Largest tumor <= 4 cm
  6. No prior SRS to the lesions which will be treated on protocol.
  7. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

    A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  8. Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

  1. Prior whole brain radiotherapy
  2. Patients with leptomeningeal metastasis. (NOTE: For the purposes of exclusion, LMD is a clinical diagnosis, defined as positive CSF cytology and/or equivocal radiologic or clinical evidence of leptomeningeal involvement. Patients with leptomeningeal symptoms in the setting of leptomeningeal enhancement by imaging (MRI) would be considered to have LMD even in the absence of positive CSF cytology, unless a parenchymal lesion can adequately explain the neurologic symptoms and/or signs. In contrast, an asymptomatic or minimally symptomatic patient with mild or nonspecific leptomeningeal enhancement (MRI) would not be considered to have LMD. In that patient, CSF sampling is not required to formally exclude LMD, but can be performed at the investigator's discretion based on level of clinical suspicion.)
  3. Patients with life expectancy < 4 months
  4. Psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.
  5. Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03508752


Contacts
Layout table for location contacts
Contact: Kajal Desai, MS 214-645-8301 Kajal.Desai@utsouthwestern.edu
Contact: Sarah Hardee, MS 214-685-8525 Sarah.Hardee@utsouthwestern.edu

Locations
Layout table for location information
United States, Texas
University of Texas Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: christian Chukwuma    214-685-8525      
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Zabi Wardak, MD UT Southwestern Medical Center
Layout table for additonal information
Responsible Party: Zabi Wardak, Assistant Professor, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT03508752    
Other Study ID Numbers: STU 122016-064
First Posted: April 26, 2018    Key Record Dates
Last Update Posted: October 15, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Brain Neoplasms
Neoplastic Processes
Neoplasms
Pathologic Processes
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases